Sirnaomics Ltd is a clinical-stage ribonucleic acid (RNA) therapeutics biopharmaceutical company. The Company is engaged in discovering and developing drugs for indications with unmet medical needs and market opportunities. The Company’s product pipeline has broad therapeutic utility across market diseases including oncology, fibrosis-related diseases as well as antiviral and cardiometabolic diseases. The Company’s targets once selected based on clear scientific rationale, it applies an algorithm based on its understanding of the biochemical mechanisms involved in RNA interference to identify candidate RNA interference (RNAi) trigger sequences against the selected target gene and employ high throughput processes to design, screen and test future pipeline products. It has five ongoing clinical trials in phase I/II stage and another at least 14 other product candidates in investigational new drug (IND) enabling or advanced preclinical studies.

© Copyright 1996-20220232 irasia.com Ltd. All rights reserved.

DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any information provided on this website. Under no circumstances shall irasia.com Ltd be liable for damages resulting from the use of the information provided on this website. TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website.